Wu Tsai Human Performance Alliance


Showing 101-110 of 255 Results

  • Gentaro Ikeda

    Gentaro Ikeda

    Instructor, Medicine - Cardiovascular Medicine

    BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.

  • Doug James

    Doug James

    Professor of Computer Science and, by courtesy, of Music

    Current Research and Scholarly InterestsComputer graphics & animation, physics-based sound synthesis, computational physics, haptics, reduced-order modeling

  • Deborah Kado

    Deborah Kado

    Professor of Medicine (Primary Care and Population Health) and, by courtesy, of Epidemiology and Population Health

    BioDr. Kado is a board-certified, fellowship-trained doctor specializing in geriatrics. She serves as co-director of the Stanford Longevity Center. She is a professor of medicine and chief of research for the Geriatrics Section in the Department of Medicine, Division of Primary Care and Population Health. She is also the Director of the Geriatric Research, Education, and Clinical Center (GRECC) at VA Palo Alto Health Care System.

    For each patient, Dr. Kado prepares a personalized care plan. Her objective is to help all individuals maintain the best possible health and quality of life as they age.

    A special interest of Dr. Kado is bone health. She has conducted extensive research focused on osteoporosis and the related disorder hyperkyphosis.
    Since joining the UCLA faculty in 2000, she has received continuous funding for her research from the National Institutes of Health (NIH).

    She has over 100 peer-reviewed publications of her research findings in the Journal of Bone and Mineral Research, Osteoporosis International, Journal of Gerontology and Medical Sciences, Journal of Geriatric Oncology, Nature Communications, and other peer-reviewed journals.

    In 2007, she defined hyperkyphosis as a new geriatric syndrome. Her discoveries in this field were first featured in the American College or Physician’s premier internal medicine journal Annals of Internal Medicine. Later, they also appeared in a dedicated chapter in UpToDate, the electronic resource providing evidence-based clinical decision support for doctors worldwide.

    Prior to coming to Stanford, Dr. Kado practiced at UC San Diego where she started a dedicated osteoporosis clinic for patient care and research. She later broadened her research interests beyond musculoskeletal aging to study other aging-related topics such as the gut microbiome in older men and the effects of cancer treatments on aging in newly diagnosed breast cancer patients.

    Dr. Kado is a California native. She trained at UCSF and UCLA. She also earned a Master of Science degree in epidemiology at the UCLA School of Public Health, sponsored by the John Hartford Foundation.

    She is a member of the American Geriatrics Society, American Society of Bone and Mineral Research, Gerontological Society of America, The Endocrine Society, and other professional organizations. She co-chairs the NIH National Institute on Aging Workshop for the American Society of Bone and Mineral Research. She also participates in the Bone Health Working Group of the Society for Women’s Health Research.

  • Robin Kamal MD MBA

    Robin Kamal MD MBA

    Associate Professor of Orthopaedic Surgery

    Current Research and Scholarly InterestsWrist and Elbow Injuries and Quality Measures in Orthopaedic Surgery

  • Monroe Kennedy III

    Monroe Kennedy III

    Assistant Professor of Mechanical Engineering and, by courtesy, of Computer Science

    Current Research and Scholarly InterestsMy research focus is to develop technology that improves everyday life by anticipating and acting on the needs of human counterparts. My research can be divided into the following sub-categories: robotic assistants, connected devices and intelligent wearables. My Assistive Robotics and Manipulation lab focuses heavily on both the analytical and experimental components of assistive technology design.

  • Khizer Khaderi MD, MPH

    Khizer Khaderi MD, MPH

    Clinical Associate Professor, Ophthalmology

    BioDr. Khizer Khaderi is a Clinical Associate Professor at the Byers Eye Institute at Stanford University. Khaderi is the Founding Director of the Stanford Human Perception Laboratory (HPL) and the Stanford Vision Performance Center (VPC). He also serves as faculty at the Stanford Institute for Human-Centered AI and the Wu Tsai Human Performance Alliance (HPA)

    Khaderi is a renowned Neuro-Ophthalmic surgeon, technologist and futurist. Dr. Khaderi is pioneering the field of Symbiotics, defined as the convergence of human science + computer science to design and develop human-centric technologies. Khaderi has extensive domain expertise in artificial intelligence (AI), spatial computing (virtual reality (VR), augmented reality (AR), mixed reality (MxR)), wearables, gaming, IoT, Web3, applied neuroscience, human factors, and human-machine interfaces/interaction. His research interests include developing personalized human intelligent systems based on the human brain and sensory systems, developing technologies to optimize human performance, and combining biological and computational principles to expand our capabilities in research, clinical practice, and everyday life. Dr. Khaderi's approach to advance research interests and develop practical applications for everyday use is building technology, companies and collaborative partnerships across academia and industry.

    Dr. Khaderi’s experience across industry sectors include consumer electronics, gaming, retail, life science, sports/Esports health care, Pharma, e-commerce, to name a few. He has developed novel technologies in these areas, and generated multiple invention patents. Selected as a “40 under 40”, he contributed to President Obama’s Council of Advisors on Science and Technology regarding vision technology and the aging population. He also advises multiple companies, venture firms and organizations including the Global Esports Federation, Magic Leap, Riot Games, Intel, Activision, Unity, Epic Games, Google, FB, Microsoft, Apple, NBA, Aerie Pharma, the World Health Organization, and the World Bank.

  • Oussama Khatib

    Oussama Khatib

    Weichai Professor and Professor, by courtesy, of Electrical Engineering

    BioRobotics research on novel control architectures, algorithms, sensing, and human-friendly designs for advanced capabilities in complex environments. With a focus on enabling robots to interact cooperatively and safely with humans and the physical world, these studies bring understanding of human movements for therapy, athletic training, and performance enhancement. Our work on understanding human cognitive task representation and physical skills is enabling transfer for increased robot autonomy. With these core capabilities, we are exploring applications in healthcare and wellness, industry and service, farms and smart cities, and dangerous and unreachable settings -- deep in oceans, mines, and space.

  • Peter S. Kim

    Peter S. Kim

    Virginia and D. K. Ludwig Professor of Biochemistry
    On Partial Leave from 09/01/2023 To 06/30/2024

    Current Research and Scholarly InterestsWe are studying the mechanism of viral membrane fusion and its inhibition by drugs and antibodies. We use the HIV envelope protein (gp120/gp41) as a model system. Some of our studies are aimed at creating an HIV vaccine. We are also characterizing protein surfaces that are referred to as "non-druggable". These surfaces are defined empirically based on failure to identify small, drug-like molecules that bind to them with high affinity and specificity.

  • Abby C. King

    Abby C. King

    David and Susan Heckerman Professor and Professor of Epidemiology & Population Health and of Medicine (Stanford Prevention Research Center)

    Current Research and Scholarly InterestsMy interests include applications of behavioral theory and social ecological approaches to achieve large scale changes impacting chronic disease prevention and control; expanding the reach and translation of evidence-based interventions through state-of-the-art technologies; exploring social and physical environmental influences on health; applying community participatory research perspectives to address health disparities; and policy-level approaches to health promotion/disease prevention.

  • Joshua W. Knowles

    Joshua W. Knowles

    Associate Professor of Medicine (Cardiovascular Medicine)

    Current Research and Scholarly InterestsGenetic basis of coronary disease
    Genetic basis of insulin resistance
    Familial Hypercholesterolemia (FH)